Interferons News and Research

RSS

Phase 2 clinical study of PEG-Interferon lambda commenced

ZymoGenetics, Inc. today announced the initiation of a Phase 2 clinical trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection (the “EMERGE” study).

27 Oct 2009

Presentations on efficacy of interferon to combat influenza

Amarillo Biosciences, Inc. (ABI) today announced that Professor Dr. Otto Haller from the Department of Virology, Freiburg University, Germany and Professor Dr. Oliver Planz from the Friedrich Loeffler Institute, Tubingen, Germany gave two separate presentations on the efficacy of interferon to combat influenza.

12 Oct 2009

Researchers study functional similarity between zebrafish and humans to fight infections

Since the human response to infection is highly complex, research to understand how people fight infection is facilitated by studying how similar processes occur in simpler organisms. Zebrafish are becoming an important model for human disease, since they are easily handled, maintained and manipulated and many fundamental processes between zebrafish and humans are conserved.

24 Sep 2009

Disruption of immune-system pathway key step in cancer progression

Human immune cells communicate constantly with one another as they coordinate to fight off infection and other threats.

18 May 2009

New discovery improves efficacy of current tuberculosis vaccine

A new article appearing in the March 2009 issue of the Journal of Leukocyte Biology may lead to improvements in the efficacy of the current tuberculosis vaccine.

26 Feb 2009

New approaches to prevent transplant rejection

To prevent the rejection of newly transplanted organs and cells, patients must take medicines that weaken their entire immune systems.

15 Feb 2009

Research to explore why lupus therapies work for some, not others

The results should shed light not only on the mechanisms behind the disease, but more broadly on the workings of our immune system, especially how our bodies churn out and "train" key combat-ready immune cells, called B-cells.

8 Feb 2009

Soviet-developed immune formula boosts immune activity

A recent study on an American-made, Soviet-developed immune formula shows the product has a significant effect on immune function.

19 Nov 2008

VioQuest Pharmaceuticals issued new U.S. patent for Lenocta

VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.

26 Aug 2008

Immune system protein accurate predictor of survival in pediatric septic shock

About 4,000 children in the United States die every year from uncontrolled infections of the body known as septic shock, and researchers are pushing the boundaries of molecular science to find new therapies that can stem the condition. But a simple measure of an immune system protein within 24 hours of being admitted to the hospital for septic shock can predict survival in children, yielding a powerful tool for diagnostics and clinical trials of new septic shock therapies, according to a research team led by Cincinnati Children's Hospital Medical Center in the Aug. 1 American Journal of Respiratory and Critical Care Medicine.

4 Aug 2008

Controlling lupus - new drug targets found

Investigators at Hospital for Special Surgery have identified two new targets for drugs aimed at controlling lupus.

17 Dec 2007

Discovery of key lupus gene

Wellcome Trust researchers have identified a key gene involved in the disease Lupus, which affects around 50,000 people in the UK, mostly women.

3 Dec 2007

LL37 peptide provides a new potential target for autoimmune disease

A human peptide that acts as a natural antibiotic against invading microbes can also bind to the body's own DNA and trigger an immune response in the absence of an infection, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in an early online publication in Nature.

17 Sep 2007

Decitabine and interferon gamma show promise for ocular melanoma that has spread

A combination of two drugs shows promise in treating a rare and therapy-resistant type of melanoma that originates in the eye and spreads to other organs, according to a new study led by Duke University Comprehensive Cancer Center researchers.

5 Sep 2007

Biological markers of narcolepsy

The first report to identify the biological markers of narcolepsy using gene expression in white blood cells finds that the MX2 gene, which is relevant to the immune system, is significantly less expressed in narcoleptics compared with normal subjects.

2 Aug 2007

Scientists clarify molecular basis of interferon action

Scientists at the University of California, Santa Barbara have made a significant discovery relating to viral infections in humans.

20 Jul 2007

Impaired anti-inflammatory response plays role in pathology of type 2 diabetes

Type 2 diabetes is classified as a metabolic disorder, but a growing number of researchers are beginning to think of it also as a disease of the innate immune system. Inflammation, a key component of the early immune response, is chronically elevated in people with type 2 diabetes.

17 Jun 2007

Dealing with emerging diseases

The outbreak of severe acute respiratory syndrome (SARS) in 2002 was a loud wake-up call for researchers studying infectious diseases.

16 May 2007

Liver center leading record number of studies to tackle hepatitis C

While many research institutions are suffering from funding cuts, Drs. Bruce R. Bacon and Adrian M. Di Bisceglie are chugging away with their usual tenacity.

27 Apr 2007

Anadys Pharmaceuticals presents data showing ANA773 promotes anti-tumor activity of killer cells

Anadys Pharmaceuticals presented data from an in vitro study showing that the active metabolite of ANA773 promotes natural killer (NK) cell-mediated anti-tumor response by inducing cytokine secretion, cytolysis of tumor cells and enhanced antibody-dependent cellular cytotoxicity (ADCC), during a poster presentation at the Annual Meeting of the American Association of Cancer Research (AACR) in Los Angeles.

18 Apr 2007